Cellectar Adds Two to Board
Cellectar Biosciences added Douglas Swirsky and Frederick Driscoll to its board of directors, the company announced recently. Swirsky is the president and CEO of GenVec and has worked at Stifel Nicolaus…
Tag Archives: Jim Caruso
Cellectar to Begin Phase II Trial
Cellectar Biosciences announced today its initiation of a Phase II clinical study of CLR 131 in patients with multiple myeloma and other hemotologic malignancies. According to a release, the study…
Cellectar Earns Japanese Patent
Cellectar Biosciences announced today the Japanese Patent Office has granted a composition of matter patent for its optical imaging phospholipid drug conjugates (PDCs), CLR 1501 and CLR 1502. “This patent…
Cellectar, WARF Reach License Agreement
Cellectar Biosciences and the Wisconsin Alumni Research Foundation announced it new license agreement for intellectual property rights covering the method of use for the company’s compound, CLR 131, in multiple…
Cellectar Biosciences Receives Patent
The U.S. Patent and Trademark Office has awarded Cellectar Biosciences a patent that covers the method of use for CLR 1603 to treat breast, lung, colorectal and prostate cancers as…
Cellectar Sees Benefits in Study
Cellectar Biosciences announced recently a clinical benefit rate of 80 percent from its Phase I clinical study of CLR 131 in patients with relapsed or refractory multiple myeloma. “The efficacy…
UW Study to Use Cellectar Compound
Cellectar Biosciences’ CLR 131, its lead therapeutic compound, will be used in a University of Wisconsin study of neck and head cancers, the organization announced today. According to a release,…
Cellectar Earns $2M SBIR Contract
Cellectar Biosciences announced today it is the recipient of the second phase of a National Cancer Institute Fast-Track SBIR contract worth $2 million. According to a release, the money will be used to…
Cellectar Issued New Patent
The U.S. Patent and Trademark Office has awarded Cellectar Biosciences a patent that covers CLR 1603, a phospholipid ether-paclitaxel conjugate, the company announced recently. “This first issued patent under our CLR CTX…
Cellectar Raises $8M in Public Offering
Cellectar Biosciences‘ public offering raised $8 million, the company announced today. “We are pleased with the results of this offering, including the underwriter’s exercise of their full over-allotment option,” Cellectar…
